Separate terms with OR to return results that match either term.
 
Clear All
716 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class (Descending) Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9017 Arsenic Trioxide Trisenox 1 mg Chemotherapy Miscellaneous Agent PML/RARa No 2000 Jan. 1, 2002 In Use
C9012 Arsenic Trioxide Trisenox unspecified Chemotherapy Miscellaneous Agent PML/RARa No 2000 Jan. 1, 2001 Dec. 31, 2001 No Longer Used
NA Umbralisib Ukoniq 260.2mg Chemotherapy Enzyme Inhibitor PI3Kδ, CK1ε, ABL1, CXCL12, CCL19 Yes 2021 In Use
NA idelalisib Zydelig 100 mg Chemotherapy Enzyme Inhibitor PI3K Yes 2014 In Use
NA idelalisib Zydelig 150 mg Chemotherapy Enzyme Inhibitor PI3K Yes 2014 In Use
J9057 Copanlisib Aliqopa 1mg Chemotherapy Enzyme Inhibitor PI3K No 2017 In Use
NA Alpelisib Piqray 200mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use
NA Alpelisib Piqray 150mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use
NA Duvelisib Copiktra 15mg, 25mg Chemotherapy Enzyme Inhibitor PI3K Yes 2018 In Use
NA Avapritinib Ayvakit 100mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Avapritinib Ayvakit 200mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Avapritinib Ayvakit 25mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Avapritinib Ayvakit 300mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Avapritinib Ayvakit 50mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
J9285 Olaratumab Lartruvo 10 mg Immunotherapy Monoclonal Antibody PDGFR No 2016 April 1, 2017 In Use
NA Anagrelide Agrylin 1mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
NA Anagrelide Agrylin 0.5mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
C9492 Durvalumab Imfinzi 10 mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2017 Oct. 1, 2017 In Use
J9022 Atezolizumab Tecentriq 10mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2016 Jan. 1, 2018 In Use
J9023 Avelumab Bavencio 10mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2017 Jan. 1, 2018 In Use
J9173 Durvalumab Imfinzi 10mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2017 Jan. 1, 2019 In Use
J9298 Nivolumab & relatlimab-rmbw Opdualag 3mg/1mg Immunotherapy Checkpoint Inhibitor, Monoclonal Antibody PD-1, LAG3 No 2022 Sept. 27, 2022 In Use
C9491 Avelumab Bavencio 10 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2017 Oct. 1, 2017 In Use
C9483 Atezolizumab Tecentriq 10 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2016 Oct. 1, 2016 In Use
J9299 Nivolumab Opdivo 1 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2014 Jan. 1, 2016 In Use

Found 716 results in 0 milliseconds — Export these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.